Novintum Bio is developing novel small molecule compounds that interfere with mitochondrial biogenesis to reduce mitochondrial metabolism in cancer cells and TRCs, known as Mitochondrial Metabolism Disruptors (MMDs). These MMDs effectively ‘switch off the engine’ that enables TRCs to survive, thereby preventing resistance and delaying relapse. In vivo studies have shown that Novintum Bio’s MMDs reduce growth in tumours in combination with standard of care.
Novintum BioScience was established in 2015 under a risk-optimized structure that includes a Swiss-based management company (Novintum Biotechnology GmbH) and is based in London, UK. The Company has raised $13 million to date from Rising Tide Foundation, a philanthropic, patient-centric organisation focused on bringing advanced treatment options to cancer patients.
Serial entrepreneur. Formerly at Merck (R&D, BD&L), Proximagen (CBO), Q Chip (CEO) & Midatech (CBO); Track record of M&A, licensing & exits of >$1bn and R&D expertise in CNS, ophthalmology & cancer
Serial entrepreneur. Formerly Rising Tide COO, currently Brown Legacy Group (Principal) & Novintum Medtech (CEO); Strategy, Corporate Structuring, Legal and IP
Translational scientist with experience in cancer R&D with Sanofi & Genticel. Over 20 compounds developed with 4 to market – Taxotere, Irinotecan, Cabazitaxel & Zaltrap
Experienced venture-capital investment and corporate/business development professional. Extensive transactional experience with Atlas Venture, Orion Healthcare, Evolva and as a private investor in early-stage biotechnology companies.